Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Trust and transparency in Pharma & healthcare: impact of the COVID-19 pandemic

July 25, 2022 | COVID-19, Virtual collaboration, digital opinion leaders, health literacy, key opinion leaders, transparency, trust 

While it is obvious that trust in life science and healthcare companies is suboptimal, exactly how to improve the public’s trust is unclear…

“…Of course, we also need to consider where (from who) the information is coming from. Doctors, pharmacists, and other health experts are more trusted than life science CEOs, government leaders, and journalists. Among healthcare institutions, academic medical research institutions are the most trusted. For Pharma, this means that establishing authentic relationships with trusted and approachable physicians, pharmacists, nurses, and academics should be a top priority. In addition to traditional key opinion leaders (KOLs), digital opinion leaders (DOLs)–an emerging group of stakeholders for Pharma to engage with–are well-positioned to share scientific data with the general public. 

Pharma teams should work directly with KOLs and DOLs, as well as with patients and caregivers, to design public-facing videos, websites, handouts, and educational campaigns in order to get the right messages across. When events that might erode public trust do occur, be open and honest with your advisors and get their input on how to respond to negative press in a transparent and sincere manner.”

Read the full article at https://www.impetusdigital.com/2022/05/10/trust-and-transparency-in-pharma/

This content was provided by Impetus Digital

Company Details

- PMLiVE

Impetus Digital

Email
Website

 Latest Content from  Impetus Digital 

Effective Communication in Virtual Meetings: Stay Pithy - Impetus InSite Tips #4

Learn the value of concise communication in our fourth tip for optimizing virtual meetings. Discover how keeping interactions short and focused can drastically improve engagement and retention in today's fast-paced...

Enhancing Honesty in Feedback: Blinded Questions

Explore our third tip in our series aimed at refining asynchronous virtual meetings. Discover how using blinded questions can significantly minimize bias and enhance the integrity of feedback in virtual...

Streamlining Asynchronous Feedback: Scale Consistency - Impetus InSite Tips #2

Uncover the second crucial tip for optimizing your asynchronous virtual meetings. Learn the importance of scale consistency in survey-style questions on the Impetus InSite Platform to ensure clear and reliable...

Clinical Trial Protocol Conceptualization: A Customer Story

To set their Phase II clinical trial of a novel anti-cancer compound up for success, our client sought early multidisciplinary insights on current unmet needs, as well as feedback on their preclinical...

Mastering Asynchronous Meetings: Open-Ended Questions - Impetus Digital Tip 1

Unlock the potential of asynchronous virtual meetings with the first tip from our "Top 10 Tips for Optimizing Asynchronous Virtual Meetings".

In-person, hybrid, or digital? State of Pharma meetings and events in 2024

We’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put the idea of in-person meetings being superior to rest.

Navigating Regulatory Challenges - Top 10 Most Important Advisor Questions

This quick video covers #9 of our Top 10 Most Important Advisor Questions, shedding light on the complexities of local and national regulatory issues in the Pharma and Life Sciences...

Top-5 Trends in Virtual KOL Engagement

Register now for one of our upcoming webinars (February 26-28)

Engaging with Different Perspectives - Top 10 Most Important Advisor Questions

In this quick clip, we highlight a vital tip from our 'Top 10 Most Important Advisor Questions' – essential for enhancing your virtual collaboration strategies in Pharma and Life Sciences....

Patient Advocate Engagement: A Customer Story

Learn how our client executed a series of 3 virtual touchpoints with 5 rare disease patient advocates to:- Develop a better understanding of the current treatment landscape and lived patient...